Ken Griffin Stealth Bio Therapeutics Corp Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.18 - $0.71 $25,420 - $100,270	141,226 New	141,226 $36,000
Q1 2022 May 16, 2022	SELL	$0.49 - $0.9 $7,944 - $14,591	-16,213 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$0.76 - $1.48 $73,131 - $142,414	-96,226 Reduced 85.58%	16,213 $0
Q1 2021 May 17, 2021	BUY	$1.38 - $2.42 $108,749 - $190,705	78,804 Added 234.29%	112,439 $177,000
Q4 2020 Feb 16, 2021	BUY	$1.27 - $1.62 $27,236 - $34,742	21,446 Added 175.95%	33,635 $50,000
Q3 2020 Nov 16, 2020	BUY	$1.32 - $2.23 $16,089 - $27,181	12,189 New	12,189 $16,000

2.94K

Ticker MITO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,548,600
Description
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duche...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.